stoxline Quote Chart Rank Option Currency Glossary
  
Theriva Biologics, Inc. (TOVX)
0.435  0.004 (0.97%)    04-17 15:58
Open: 0.43
High: 0.45
Volume: 20,900
  
Pre. Close: 0.4308
Low: 0.4204
Market Cap: 7(M)
Technical analysis
2024-04-17 4:50:04 PM
Short term     
Mid term     
Targets 6-month :  0.67 1-year :  0.79
Resists First :  0.57 Second :  0.68
Pivot price 0.44
Supports First :  0.4 Second :  0.34
MAs MA(5) :  0.43 MA(20) :  0.46
MA(100) :  0.48 MA(250) :  0.55
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  7.3 D(3) :  8.1
RSI RSI(14): 45.4
52-week High :  1.2 Low :  0.2
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TOVX ] has closed above bottom band by 31.1%. Bollinger Bands are 63.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.45 - 0.45 0.45 - 0.46
Low: 0.41 - 0.42 0.42 - 0.42
Close: 0.43 - 0.44 0.44 - 0.44
Company Description

Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.

Headline News

Tue, 16 Apr 2024
Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Diff - Benzinga

Tue, 16 Apr 2024
Theriva Biologics (NYSEAMERICAN:TOVX) Trading Down 3.7% - Defense World

Mon, 08 Apr 2024
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting - GlobeNewswire

Tue, 26 Mar 2024
Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript - Yahoo Finance

Mon, 25 Mar 2024
Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript - Seeking Alpha

Mon, 25 Mar 2024
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 17 (M)
Shares Float 17 (M)
Held by Insiders 1.9 (%)
Held by Institutions 6.2 (%)
Shares Short 385 (K)
Shares Short P.Month 413 (K)
Stock Financials
EPS -1.25
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.41
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -21.2 %
Return on Equity (ttm) -37.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.39
Qtrly Earnings Growth 0 %
Operating Cash Flow -18 (M)
Levered Free Cash Flow -21 (M)
Stock Valuations
PE Ratio -0.35
PEG Ratio 0
Price to Book value 0.18
Price to Sales 0
Price to Cash Flow -0.42
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android